
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has demonstrated impressive growth potential, particularly with its point-of-care (POC) and formulary offerings, which experienced over 100% growth during the recent buying season. The company's shares have shown resilience and a positive trend, increasing by 3.2% since September 8, indicating investor confidence in its performance and future prospects. Additionally, the company’s second-quarter guidance appears not only achievable but also presents opportunities for upward revision, supported by enhanced visibility and upfront buying from expanded service offerings.
Bears say
Doximity faces a negative outlook primarily due to downward guidance revisions from its pharmaceutical clients, driven by an uncertain economic environment that suggests a potential decline in revenue for fiscal years 2023 and 2024. Furthermore, the company’s stock appears expensive relative to its software peers, which raises concerns about its valuation amid high investor expectations. The potential for volatility in share prices is significant, particularly if Doximity fails to meet projected financial results or provide upward guidance, which could lead to investor disappointment.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares